Home
/
PUMA BIOTECHNOLOGY, INC.
/
Financials
/
Quarterly
PUMA BIOTECHNOLOGY, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PUMA BIOTECHNOLOGY, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$66.52M
May 10, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$54.48M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$52.44M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$46.01M
May 8, 2025
Q3
2025
Sep 30, 2024
$80.54M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$47.08M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$43.77M
May 8, 2025
Q3
2024
Sep 30, 2023
$56.12M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$54.57M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$52.78M
May 2, 2024
Q3
2023
Sep 30, 2022
$57.10M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$59.52M
Aug 3, 2023
Q1
2022
Mar 31, 2022
$45.74M
May 4, 2023
Q3
2022
Sep 30, 2021
$46.25M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$53.38M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$98.17M
May 5, 2022
Q3
2021
Sep 30, 2020
$50.75M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$70.58M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$51.22M
May 6, 2021
Q3
2020
Sep 30, 2019
$56.35M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$53.92M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.84M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$5.86M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$2.97M
May 8, 2025
Q3
2025
Sep 30, 2024
$20.32M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($4.53M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($4.82M)
May 8, 2025
Q3
2024
Sep 30, 2023
$5.80M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$2.13M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$1.40M
May 2, 2024
Q3
2023
Sep 30, 2022
($360.0K)
Nov 2, 2023
Q2
2023
Jun 30, 2022
$9.37M
Aug 3, 2023
Q1
2022
Mar 31, 2022
($3.40M)
May 4, 2023
Q3
2022
Sep 30, 2021
($44.67M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($5.11M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
$16.53M
May 5, 2022
Q3
2021
Sep 30, 2020
($31.46M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
$3.40M
Aug 5, 2021
Q1
2021
Mar 31, 2020
($16.93M)
May 6, 2021
Q3
2020
Sep 30, 2019
($16.89M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($37.42M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$9.57M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$6.64M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$3.98M
May 8, 2025
Q3
2025
Sep 30, 2024
$22.08M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($2.18M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($2.30M)
May 8, 2025
Q3
2024
Sep 30, 2023
$8.59M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$4.89M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$4.37M
May 2, 2024
Q3
2023
Sep 30, 2022
$2.39M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$12.06M
Aug 3, 2023
Q1
2022
Mar 31, 2022
($747.0K)
May 4, 2023
Q3
2022
Sep 30, 2021
($8.95M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($16.63M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
$20.15M
May 5, 2022
Q3
2021
Sep 30, 2020
($12.13M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
$7.13M
Aug 5, 2021
Q1
2021
Mar 31, 2020
($14.25M)
May 6, 2021
Q3
2020
Sep 30, 2019
($14.45M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($25.78M)
Aug 6, 2020